COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases

Author(s): Fereshteh Ghiasvand, Maryam Ghadimi, Sara Sadr, Fatemeh Jafari, Navid Manafi, Zahra Ahmadinejad, Samaneh Tirgar, Seyed Ahmad Seyed Alinaghi*

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Volume 21 , Issue 6 , 2021


Article ID: e170721188439
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Azithromycin has been considered as a possible therapeutic agent for COVID-19 patients. However, there is limited data on its efficacy.

Case Presentation: We describe three patients diagnosed with COVID-19 who did not respond to the initial treatment but improved dramatically upon adding azithromycin with a successful outcome.

Conclusion: We have presented evidence of the potential beneficial effect of the azithromycin in the treatment of patients with COVID-19 in three different clinical settings. More evidence is needed regarding the microbiological data, safety, and efficacy of this medication in the management of COVID-19.

Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19), hydroxychloroquine, azithromycin, atazanavir, ritonavir.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 6
Year: 2021
Published on: 26 November, 2020
Article ID: e170721188439
Pages: 5
DOI: 10.2174/1871526520999201126203510
Price: $65

Article Metrics

PDF: 236